Pharmicell announced on the 20th that it presented research on the discovery of biomarkers for predicting treatment responsiveness of stem cell therapy for acute myocardial infarction at the '2025 Korean Society of Cardiovascular Intervention (KSCI) Scientific Conference.'
Dr. Lim Ji-seon of Pharmicell, who gave the presentation, explained, "We divided patients treated with Hearticellgram-AMI into responder (R) and non-responder (NR) groups based on treatment effects and compared the characteristics of stem cells," adding, "We confirmed superior stem cell capabilities in the responder group."
She continued, "Through multi-omics analysis, an integrated method of transcriptome, single-cell transcriptome, and proteome analysis, we identified candidate biomarkers that determine the differing treatment responsiveness of the stem cell therapy."
Dr. Lim advised, "The targets discovered through multi-omics (RNA seq, scRNA seq, Proteomics) analysis in this study will be utilized as indicators to predict the responsiveness to Hearticellgram-AMI." She also stated, "This research is expected to expand into developing next-generation stem cell therapies with enhanced functions by predicting the efficacy of allogeneic cell production."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
